Supplementary Materialsmicroorganisms-08-00742-s001. while mutants in oxidative stress response and general stress response were generally retrieved upon treatment with some other drug. The data presented suggest that nortriptyline Verteporfin enzyme inhibitor can be considered a new antimicrobial drug with large potential for software to in vivo illness models. spp. are probably one of the most frequent nosocomial pathogens often causing bloodstream infections [1], and with the capacity to develop resistance to popular antifungals. To fight Rabbit Polyclonal to MGST1 this problem, drug repurposing [2,3] along with the recognition of new active molecules and fresh combination strategies [4,5] are becoming investigated. Thanks to drug repositioning, ibuprofen has recently been verified to be efficient against biofilms [6], while auranofin offers been shown to be a strong antimicrobial [7]. Moreover, sertraline, an antidepressant inhibiting the selective reuptake of serotonin, was shown to induce autophagy in [8], and its antifungal activity is now being evaluated with in vivo illness models of [9] and [10]. Nortriptyline (NOR), the most used tricyclic antidepressants (TCA) up until the intro of selective serotonin re-uptake inhibitors, or SSRIs, was shown to have the capacity to inhibit biofilm and hyphae formation and to efficiently get rid of cells in a mature biofilm of [11]. NOR induces lysis of cells [11], an effect also displayed upon treatment with local anesthetics [12] and antipsychotic phenothiazine [13]. This trend is related to their amphiphilic constructions and their surfactant activity, which are able to disturb cell membrane features [11,13]. Interestingly, NOR is now also employed in clinical trials focused not Verteporfin enzyme inhibitor only on depression, but also on atopic dermatitis, psoriasis vulgaris, irritable bowel syndrome, and gastro-esophageal reflux disease (www.drugbank.ca/drugs/DB00540). In order to propose NOR as a new antimicrobial, on its own or in combination with known antimicrobials to potentiate their actions, it is important to characterize in more detail the effects of this drug on the pathogenic yeast GRACE? collection and a HIP approach were used to identify the potential targets of NOR by comparing its action with that of three known antimicrobials: amphotericin B (AMB), caspofungin (CAS), and fluconazole (FLU), in order to classify NOR specific targets and general multi-drug resistance (MDR) genes. In addition, tests on oxidative stress, mutagenicity, and expression of drug transporters were performed. 2. Materials and Methods 2.1. Strains and Media The GRACE? mutant Verteporfin enzyme inhibitor collection (2372 strains) [18] was obtained in the CaSS1 background by replacing one copy of the target gene with a cassette containing the selectable marker flanked by the necessary homologous sequences and two distinct bar codes, and by swapping the promoter region of the second copy of the gene with a cassette containing the tightly regulated tetracycline promoter, which is repressed when the media is supplemented with tetracycline. In this screening, no tetracycline was employed (except for selected mutants reported in Supplementary Figure S1), allowing the expression of one active copy of the gene of interest and the employment of HIP assay [16]. Strains were grown either in YPD (Yeast extract-Peptone- Dextrose) or in RPMI-1640 (Roswell Park Memorial Institute-1640) (Thermo Fisher Scientific Inc., Waltham, MA, USA) with 2% glucose as specified. Bacteria strains TA98 and TA100 were kindly provided by Prof. R. Scarpato (Dep. of Biology, University of Pisa, Italy) and grown in Nutrient Broth Oxoide no.2 (Thermo Fisher Scientific Inc., Waltham, MA, USA). 2.2. Testing Drug Working Concentrations The first step was to identify a concentration for each drug that allowed a clear identification of the growth phenotype (GP) displayed by the mutants. Specifically, concentrations that allowed growth of wild type (WT), but not of sensitive mutants (condition A), and concentrations where the.